爱硒健康,提供乳腺癌、肺癌等癌症康复前期预防及后期癌症康复计划

ESMO速报:初治EGFR突变非鳞状NSCLC患者如何选择?奥希替尼单药or奥希替尼+贝伐珠单抗?

转发文章到朋友圈,扫描二维码或微信623296388,截屏给硒教授,赠癌症食疗电子书

编者按:

  • l FOLFOXIRI/贝伐珠单抗方案中添加阿替利珠单抗可延长转移性结直肠癌患者无进展生存期——LBA20—FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as fifirst-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO.

  • l 对于初治EGFR突变非鳞状NSCLC患者,奥希替尼单药好还是联用贝伐珠单抗好?——LBA44—primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study.

  • l ToGA方案如何优化?曲妥珠单抗+纳武利尤单抗+FOLFOX进一步改善食管胃腺癌患者总生存率!——LBA45—Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) – results of the randomized phase 2 INTEGA trial (AIO STO 0217).

 

– End –

加硒教授微信:623296388,送食疗电子书,任选一本

本文来自互联网,若有版权问题,请联系编辑及时删除。癌症康复-广东爱硒健康管理有限公司官网 » ESMO速报:初治EGFR突变非鳞状NSCLC患者如何选择?奥希替尼单药or奥希替尼+贝伐珠单抗?

分享到:更多 ()

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址

提供乳腺癌、肺癌等癌症康复前期预防及后期癌症康复计划

联系我们硒教授微信:623296388